Key Speakers
• Dr Laurent Audoly, Senior Director, Biologics Research, Merck
• Dr Kevin Johnson, Chief Executive Officer, PanGenetics
• Dr Steve Coats, Director of Oncology, Research and Development, MedImmune
• Dr Jeannick Cizeau, Director, Research, Viventia Biotechnologies
• Dr Surinder K Sharma, Group Head: ADEPT Biology & Translational Therapeutics, CR-UK Targeting & Imaging Group, UCL Cancer Institute
• Dr René Hoet, Sr. Director, Research, Genmab
• Dr Matthew Baker, Chief Scientific Officer, Antitope
• Philippe Stas, Chief Executive Officer, Algonomics
• Dr Leon Hooftman, Chief Medical Officer, Chroma Therapeutics
• Professor Agamemnon A. Epenetos, Chairman, Trojantec
• Franck Perez, Research Director, Institut Curie
• Philip Webber, Partner - Patent Attorney, Frank B. Dehn & Co
• Marianne Groeneveld, Senior Regulatory Affairs Manager Pharma, TNO Quality of Life
• Dr Arno Kromminga, Institute for Immunology, Pathology and Molecular Biology, IPM-Biotech
• Professor Roy Jefferis, Molecular Immunology, The Division of Immunity & Infection, University of Birmingham
• Dr Yuehua Cong, Research Scientist, PolyTherics
• Dr Alois B. Lang, Professor of Immunology, Director of Development, GeNeuro
• Dr Yi Li, Head of Protein Engineering Group, Immunocore
• Dr Tobias Raum, Senior Director Lead Discovery - Human Antibody Technologies, Micromet

Recombinant protein technologies are now standard and the current focus has shifted from the method of bulk production to post-production techniques that promise to enhance stability and delivery. In the effort to produce orally available therapeutics, formulation issues have become critical. (Source: BCC)

Advances in recombinant antibodies have impact on a range of therapy areas, such as oncology, CNS, infectious and inflammatory diseases. With an expert line-up of speakers, Visiongain’s 3rd Annual Recombinant Antibodies Conference is an ideal forum for industry and academia alike. This 2-day event will explore novel applications of antibodies, recent advances in antibody engineering and the latest clinical developments.

By attending this conference you will:
• Examine future trends in global antibody development
• Hear the latest strategies for protecting antibodies and receive relevant regulatory information
• Reduce immunogenicity risk by overcoming immune reactions to improve clinical applications of antibody therapeutics
• Explore recent developments in antibody therapy against infl ammatory/ autoimmune diseases
• Improve clinical study design
• Hear case studies on developments of recombinant antibodies as cancer therapeutics

Target Audience:
• Pharmaceutical and biotechnology companies
• Regulatory agencies/ associations / law firms
• Contract research and manufacturing organisations (CROs and CMOs)
• Generic companies
• Venture Capitalists
• Academia

Who will be there?
• VPs, Directors, Heads and Managers of:
• Research & Development with an interest in protein and peptide technology
• Protein/ Antibody Engineering
• Antibody Development
• Antibody Technology
• Therapeutic Antibodies
• Immunology (Research)
• Immunogenicity
• Drug Formulation
• (Clinical) Oncology
• Oncology Discovery/ Research
• Oncology Discovery
• Analytical Chemistry
• Preclinical Development
• Clinical Development
• Regulatory Affairs/ IP/ Patents
• New product development
• Business Development
• Marketing
• Licensing